Article

When hope becomes reality

Author(s):

Last week I talked about my friend Karen and her move into that place called hopeful reality as her options for treatment ended and she chose a clinical trial for her advanced endometrial cancer. She began the clinical trial on Monday, July 23, her 56th birthday, with high hopes that the drug would begin to do its magic and slow the growth of what she knew was a very aggressive tumor. But there wasn't even time for the drug to get a good foothold before pain meant a hospitalization and fever of unknown origin that indicated an infection somewhere that the doctors couldn't determine. By Thursday, Karen was on antibiotics and morphine, hoping a few days of each would allow her medical team to analyze and fix the problem. But as often happens with cancer, the problem was the cancer. On Sunday, I spent the night with her and we talked about how hope had changed from months to long enough to say goodbyes. With her pain under control and her fever close to normal, she discussed ways that she might have a week to travel to her favorite city in New Mexico where she had lived for a number of years. She wanted to breathe the air and say goodbye to the mountains she had hiked so often. Then she would return to hospice. Today she finished a week of radiation treatments, and her plan is to leave this weekend for her final trip to say goodbye to friends and places. We worry for her and her health as she takes this final trip, but we honor her need to go.

Related Videos
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.